drugset / Trial / NCT02156544

Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519

NCT02156544

Phase 1 Completed 41 enrolled Chong Kun Dang Pharmaceutical
RandomizedDouble-blindTreatment

Summary

The purpose of this study is to investigate the safety/tolerability and pharmacokinetics/pharmacodynamics of CKD-519.

Timeline

Start
2014-06
Primary completion
2014-10
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ROCACETRAPIB Small molecule 25 mg Oral
Subject ROCACETRAPIB Small molecule 50 mg Oral
Subject ROCACETRAPIB Small molecule 100 mg Oral
Subject ROCACETRAPIB Small molecule 200 mg Oral
Subject ROCACETRAPIB Small molecule 400 mg Oral

Indications